tbuckley/cabot-search huggingface dataset:
Platelet-Endothelium Interactions
Authors: Jeffrey S. Flier, Lisa H. Underhill, J. Anthony Ware, Donald D. Heistad
Journal: New England Journal of Medicine (1993)

The recognition that the restoration of patency to occluded blood vessels can improve clinical outcomes has led to intense interest in the formation and dissolution of platelet thrombi and in the pathobiologic features of vascular repair after an injury. To study these events in an experimental model, many investigators challenge isolated platelets or endothelium with stimuli that represent physiologic or pathologic mediators, such as thrombin or adenosine diphosphate (ADP), and find that these agonists cause the generation of intracellular mediators that can markedly alter the function of each cell type. A critical facet of thrombus formation and vascular response to . . .
Abstract 1985: Identification of differentially expressed genes using annealing control primer (ACP)-based GeneFishing PCR technique in serous ovarian carcinoma of Korean women
Authors: Dae Han Choi, Sumi Bae, Jeong Shick Kim, Dong Han Bae, Kwang-Hyun Baek, Woong Shick Ahn
Journal: Cancer Research (2010)

Abstract Object : Ovarian cancer is the most lethal among gynecologic neoplasmas in women more than 60% of ovarian cancer is serous cystadenocarcinoma. The aim of this study is to discover different genes expression profiles between serous cystadenocarcinoma of ovary in Korean women and normal ovarian tissue. Methods : Twenty ovarian serous cystadenocarcinoma specimens were obtained from the Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea. We used a common reference as a control Stratagene (www.stratagene.com). The profiles of expressed genes were discovered from the ovarian cancer using annealing control primer (ACP)-based GeneFishing polymerase chain reaction (www.seegene.co.kr), screened by a BLAST search, and confirmed by quantitative reverse transcription-PCR (qRT-PCR). Results : In the study, about 173 differential expressed genes were identified between normal and ovarian serous cystadenocarcinoma samples, 105 of differentially expressed genes were identified more than 2-folds, 68 up-regulated and 37 down-regulated genes were sequenced. Up-regulated genes were DC_UbP, mitochondrial respiratory proteins, secretoglobin, gelsolin, actinin, cox2, sarcoglycan, VTCN1, DYNEIN, S100 A10, IFI27, EIF4A1, IFITM1, B-cell translocation protein 1, PPA1, NDRG1, HLA-DRA, COL11A1, BAZ2B, RAD54L, PRDX1, SMAD5, ELF3, SSBP1, HSBP1, TFG, SP3 etc. and down-regulated genes were MYH11, TIMP1, CYP21A2, Myo15, complement component1(C1S), FOXP1, Ku etc. Among 105 clones selected by ACP-based GeneFishing PCR, 57 genes (46 up-regulated and 11 down-regulated genes) with different expression patterns were determined and all these were confirmed by quantitative real time RT-PCR. Especially qRT-PCR analysis showed that SSBP1, HSBP1, TFG and SP3 genes were up expressed, and C1S gene was down expressed in 100% (20/20) patients with serous ovarian carcinoma. Conclusion : We identified the five highly expressed genes in serous ovarian adenocarcinoma using ACP-based GeneFishing PCR technique in Korean women. The detail functions of those genes and their products remain to be determined, the genes will provide insights into mechanisms of carcinogenesis or tumor progression in serous ovarian carcinoma in Korean women. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1985.
AB0241 Rheumatoid Arthritis Patients in Australian Database Show Significant Improvement in Disease Activity over 5 Years
Authors: G. Littlejohn, L. Roberts, P. Bird, J. de Jager, H. Griffiths, D. Nicholls, J. Young, J. Zochling, K.E. Tymms
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Rheumatoid arthritis (RA) treatment in Australia has undergone significant change in the last decade. New treatment paradigms of treat to target, with remission being the goal, supplemented by maintenance of tight control have become standard of care. We have established a network database, named OPAL-QUMI (Optimising Patient outcome in Australian RheumatoLogy – Quality Use of Medicines) whereby patient-specific details are captured on purpose-written software at the time of consultation. This information represents real-life data reflecting everyday care of the patient. We used this database to assess surrogates of disease activity over the 5-year period that our consortium has been in place (2009-2013). <h3>Objectives</h3> To evaluate the disease activity trends in rheumatoid arthritis (RA) patients in Australia over 5 years. <h3>Methods</h3> RA patients treated in participating Australian clinics were included in the study. Patient demographics, disease onset, medications and disease measures were analysed. Data, de-identified to the patient, clinic and clinician was captured using an electronic clinical management programme. The disease activity score (DAS28) was used to classify patients into the disease activity states of remission, low disease activity (LDA), moderate disease activity (MDA) and high disease activity (HDA). Choice of therapy was at the discretion of the treating clinician. <h3>Results</h3> A total of 8,458 patients, 72.3% female, 27.3% male with mean age 62.1 (SD 13.9) years and mean disease duration of 13.0 (SD 10.9) years were analysed. There were 31,023 individual DAS28 ESR values recorded in the patient group. Of these patients 45.6% were in remission, 17.1% in LDA, 28.1% in MDA and 9.2% in HDA. The percentage of patients in remission increased from 37.4% (2009) to 52.5% (2013) over the 5-year analysis period, with those in MDA falling from 32.7% to 23.5%, with reduction also in LDA from 19.1% to 16.15% and HDA from 10.8% to 7.9%. The use of biologic disease modifying antirheumatic drugs increased from 22.8% to 37.9% over the same time period. <h3>Conclusions</h3> Serial cross-sectional assessment of this large cohort of Australian RA patients showed significant increases in lower disease activity scores, with more patients in the remission and less in moderate disease activity groups over 5 years. Contemporary management of RA in Australia shows improvement in disease activity targets. <h3>Disclosure of Interest</h3> G. Littlejohn: None declared, L. Roberts: None declared, P. Bird: None declared, J. de Jager: None declared, H. Griffiths: None declared, D. Nicholls: None declared, J. Young Employee of: Roche Products, Pty. Limited, J. Zochling: None declared, K. Tymms: None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4834
Abstract 1162: RNA expression analysis of rare tumor cells by laser-mediated lysis
Authors: Fredrik Kamme, Gary Bright
Journal: Cancer Research (2010)

Abstract Molecular analysis of live rare cells, such as circulating tumor cells (CTCs) is challenging. Current strategies include antibody-mediated capture and size selection and are limited in the purity and recovery of the cells of interest. We have developed a novel approach for rare cell analysis based on the specific lysis of targeted cells in a background of a vast majority of other cell using a precisely targeted laser pulse. Instantly lysed cells release their contents into the medium, including mRNA, providing a method to analyze mRNA content in selected cells. Using a high throughput plate cytometer equipped with lasers for in situ cell manipulation (LEAP Cell Processing and Purification Workstation), we have analyzed RNA from individual tumor cells in a model of CTCs consisting of carcinoma cells spiked into human PBMCs. A 5-gene panel was measured by RT-PCR from single tumor cells and was detected in 94% of the cases with 0% false positives. RNA analysis of single tumor cells via laser-mediated lysis represents a new principle for the analysis of rare cells, as the specificity of analysis is dependent on imaging and laser targeting only and free of any limitations imposed by an antibody- or size-dependent purification strategy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1162.
Refractory Idiopathic Thrombocytopenic Purpura Treated with Azathioprine
Authors: Bertha A. Bouroncle, Charles A. Doan
Journal: New England Journal of Medicine (1966)

OUR results in the treatment of idiopathic thrombocytopenic purpura with splenectomy and corticosteroids have previously been reported. In our overall, long-term, evaluation of 271 patients with idiopathic thrombocytopenic purpura 7.7 per cent failed to respond to either method of therapy, and 4.4 per cent subsequently died from fatal bleeding.1 Over the past six years there has been an increasing interest in the suppression of the immune response by antimetabolites.2 3 4 5 6 7 8 9 10 Schwartz and Dameshek11 first reported their encouraging results in the treatment of autoimmune hemolytic anemia with 6-mercaptopurine or thioguanine.Azathioprine, 6-(1-methyl-4-nitro-5-imidazolyl)-thiopurine, B.W. 57–322, developed in recent years, is related to 6-mercaptopurine . . .
AB0383 Relationship of RA disease activity classifications and medication usage with ethnicity:
Authors: G. Kerr, Y. Yazici, Y. Sherrer, R. Nair, E. Treadwell, A. Mosley-Williams, L. Espinoza, I. Garcia-Valladares, A. Ince, J. Huang, C. Nunziato, W.A. McCracken, C. Swearingen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Advances in treatment for RA and focus on “treating to target” has led to increased use of disease activity measures in routine care. Little data exists regarding disease activity in ethnic minorities. The Ethnic Minority Rheumatoid Arthritis Consortium (EMRAC) is a registry comprise of RA clinical measures obtained during routine care. <h3>Objectives</h3> To evaluate RA disease activity levels and use of DMARDs and biologic agents in ethnic minorities. <h3>Methods</h3> RA patients of self-reported ethnicity from 9 US sites are enrolled. Demographics, comorbidities, treatments, disease activity composite scores (RAPID3, CDAI, and DAS289) were collected. Analyses of differences in clinical variables in racial groups was performed using Kruskal-Wallis for continuous variables and exact tests for qualitative variables; post-hoc pairwise comparisons between racial groups were made with the Wilcoxon rank sum test and adjusted using the Bonferonni correction (p&lt;0.008 for significance). <h3>Results</h3> 502 RA patients were enrolled (Table). For the RAPID3, DAS28, and CDAI there were not any significant racial differences between categories. Differences between races existed in medications, classified as neither DMARD or biologic, DMARD only, biologic only, and both DMARD and biologic medications. African-Americans had a smaller percentage of patients than Caucasians or Hispanics for biologic use and were more likely to be on DMARDs only rather than combination treatments. <h3>Conclusions</h3> Although differences exist in RA treatments amongst ethnic groups, current RA composite disease activity scores appear to be similar. Further analysis is needed to evaluate these findings. <h3>Disclosure of Interest</h3> G. Kerr Grant/Research support from: Genentech and Biogen IDEC, Inc, Y. Yazici Grant/Research support from: Abbott, BMS, Centocor, Genentech, Consultant for: Abbott, BMS, Genentech, Celgene, UCB, Y. Sherrer Grant/Research support from: AstraZeneca, Mercke, UCB, Sanofi Adventis, Celgene, Lily, Roche, Amgen, Wyeth, Pfizer, Novartis, Speakers Bureau: AstraZeneca, Human Genome Science, Amgen, Pfizer, Wyeth, R. Nair: None Declared, E. Treadwell: None Declared, A. Mosley-Williams: None Declared, L. Espinoza: None Declared, I. Garcia-Valladares: None Declared, A. Ince: None Declared, J. Huang: None Declared, C. Nunziato: None Declared, W. McCracken: None Declared, C. Swearingen: None Declared
Abstract 4709: miR-337-3p and its targets STAT3 and RAP1A modulate paclitaxel sensitivity in non-small cell lung cancers (NSCLCs)
Authors: Liqin Du, Maria C. Subauste, Michael Baker, Christopher DeSevo, Robert Borkowski, Shihua Zhong, Jeoffrey J. Schageman, Rachel Greer, Chin-Rang Yang, Luc Girard, Adi F. Gazdar, Ignacio I. Wistuba, John D. Minna, Alexander Pertsemlidis
Journal: Cancer Research (2011)

Abstract We are addressing the questions of whether microRNAs (miRNAs) play a functional role in modulating drug sensitivity of lung cancer cells, and whether miRNA expression levels can be manipulated to increase drug sensitivity in lung cancer treatment. Using a combination of in silico and in vitro approaches, we identified miR-337-3p as a modulator of paclitaxel sensitivity in NSCLC cell lines where over-expression of miR-337-3p sensitizes NSCLC NCI-H1155 cells to paclitaxel (&amp;gt;2 fold) and docetaxel (&amp;gt;10 fold) by enhancing taxane-induced mitotic arrest. Of several possible targets of miR-337-3p we found that Stat3 and Rap1A are the direct targets responsible for mediating miR-337-3p sensitization to paclitaxel. In studies of multiple NSCLC lines we found that miR-337-3p can, in general, sensitize NSCLC lines to paclitaxel, and that Stat3 expression is significantly correlated with paclitaxel resistance in NSCLC lines, suggesting that tumor Stat3 expression is an intrinsic determinant and biomarker for paclitaxel response. We conclude we have discovered a novel pathway modulating NSCLC paclitaxel sensitivity, which involves the down-regulation of Stat3 and Rap1A expression by miR-337-3p. These findings have prompted: our ongoing studies of patient samples annotated for miR-337-3p, Stat3, and Rap1A expression and response to taxane therapy; preclinical testing of a miR-337-3p mimic as an adjuvant to taxanes for NSCLC therapy; and further tests of this pathway to provide both new therapeutic targets and biomarkers predictive of response for NSCLC taxane based therapy. This research was supported by NIH R01 CA129632 from the National Cancer Institute and by P50 CA70907 from the UT Southwestern/MD Anderson Cancer Center Lung Specialized Program of Research Excellence. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4709. doi:10.1158/1538-7445.AM2011-4709
Half of learning disability services do not meet minimum standards of care
Authors: I. Torjesen
Journal: BMJ (2012)

Half of all care homes and treatment centres in England that care for vulnerable adults do not provide services that meet minimum standards, an inspection by the health regulator the Care Quality Commission (CQC) has found.1

The Department of Health asked the commission to undertake a series of unannounced inspections of services for people with learning disabilities or autism and challenging behaviour as part of a wide review of how the health and care system supports this group of people. The review was prompted by a BBC Panorama documentary that filmed verbal and physical abuse of residents at the Winterbourne View home near Bristol.2 A subsequent CQC investigation found that staff at Winterbourne View were too ready to use restraint and that 10 essential …
QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction
Authors: Jacob Joseph, Brian C. Claggett, Inder S. Anand, Jerome L. Fleg, Thao Huynh, Akshay S. Desai, Scott D. Solomon, Eileen O’Meara, Sonja Mckinlay, Bertram Pitt, Marc A. Pfeffer, Eldrin F. Lewis
Journal: JACC Heart Failure (2016)
Complete small-bowel examination by oral single-balloon enteroscopy using the water-exchange method
Authors: Shuhui Liang, Yanglin Pan, Biaoluo Wang, Hui Luo, Xianmin Xue, Junsheng Qin, Xuegang Guo, Kaichun Wu
Journal: Endoscopy (2013)

Large volumes of either air or carbon dioxide need to be insufflated for good visualization during enteroscopy. This leads to significant distension of the small bowel and makes further intubation technically challenging because of the formation of loops and acute angulations [1]. The rate of complete examination is only 12.4 ± 9.8 % for single-balloon enteroscopy (SBE) [2]. It is even more difficult, if not impossible, to achieve complete small-bowel examination using only the antegrade route for SBE. A device equipped with a decompression side tube seems promising with regard to extending the intubation depth during enteroscopy by air desufflation. However, the clinical outcomes of this method are awaited [3]. Herein, we report a case in which complete examination of entire small bowel was performed using only antegrade SBE with the water-exchange method.
Abstract 2907: Role of reactive oxygen and nitrogen species in resveratrol-induced lung cancer cell death.
Authors: Elizabeth S. Monillas, Grayson Walker, Aubrey Brockmiller, Anand Iyer, Neelam Azad
Journal: Cancer Research (2013)

Abstract Lung cancer is the leading cause of cancer related deaths worldwide. In 2008, 158,592 deaths were attributed to this disease and 208,493 new cases were diagnosed in the United States. Resveratrol (trans-3, 5, 4′-trihydroxystilbene), a compound found largely in the skins of red grapes, has been reported to be a promising anticancer agent in various types of cancer. The primary goal of this study is to delineate the key signaling pathways induced in response to resveratrol leading to lung cancer cell death. In this study, we use non-tumorigenic human bronchial epithelial (BEAS-2B) and human lung epithelial cancer (H460) cells to model the response of lung tissue to resveratrol. We observed an increase in superoxide, hydrogen peroxide and nitric oxide production in response to resveratrol treatment in lung cancer cells (H460) as compared to non-tumorigenic cells (BEAS-2B). Additionally, our data shows an increase in BEAS-2B cell viability as compared to H460 cell viability in response to resveratrol treatment. Overall, we observe an increase in cellular oxidative and nitrosative stress in cancer cells in response to resveratrol treatment which may be responsible for increased apoptosis and decreased viability in these cells. Subsequently, we plan to identify the specific reactive species as well as the major apoptotic pathway induced in response to resveratrol treatment in both normal and cancer cells. We expect resveratrol to have significant effect on lung cancer cells via oxidative/nitrosative stress-mediated modulation of key apoptotic biomarkers. This study will establish the protective role of resveratrol in the pathogenesis of lung cancer and the information can be potentially exploited to improve future lung cancer therapies. Citation Format: Elizabeth S. Monillas, Grayson Walker, Aubrey Brockmiller, Anand Iyer, Neelam Azad. Role of reactive oxygen and nitrogen species in resveratrol-induced lung cancer cell death. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2907. doi:10.1158/1538-7445.AM2013-2907
Abstract 3643: Manipulation of HuR expression alters the efficacy of PARP-inhibitors in pancreatic and ovarian cancer cells
Authors: Christina L. Costantino, Nathan G. Richards, Joseph Cozzitorto, David Rittenhouse, Greg Gonye, Charles J. Yeo, Agnes Witkiewicz, Jonathan R. Brody
Journal: Cancer Research (2010)

Abstract PARP-inhibitors (PARPi) are a novel class of agents that target cancer cells deficient in DNA repair. Early phase trials show promising success with PARP-inhibitors, yet drug resistance mechanisms and off-target pathways affected by drug exposure have not been explored. HuR (ELAV1) is a protein that binds and stabilizes mRNA transcripts upon certain stress stimuli. These HuR mRNA targets result in an increase in protein expression; and thus, protein function. Recently, we demonstrated that HuR binds and regulates deoxycytidine kinase, the gemcitabine metabolizing enzyme. Thus, HuR expression enhances gemcitabine efficacy against pancreatic cancer cells. We subsequently screened other chemotherapeutics that may stimulate the HuR stress response. In isogenic pancreatic cancer cell lines, stable HuR overexpression rendered cells up to 2-fold more sensitive to PARPi compared to control cells. Accordingly, siRNA knock down of HuR expression in both pancreatic and ovarian cancer cell lines caused PARPi resistance compared to a scramble-sequence control siRNA. In a pancreatic cancer cell line, MiaPaCa2, a 2.5-fold siRNA knock down of HuR mRNA expression detected by qPCR rendered cells approximately 4-fold more resistant to PARPi. Similarly, a modest siRNA knock down of HuR in an ovarian cancer cell line, A2780, rendered cells more resistant to PARPi. Immunofluorescence studies indicate that a 5 hour treatment with 75 µM PARPi directly caused HuR to transport from the nucleus to the cytoplasm, presumably moving ARE-rich mRNA cargoes after drug exposure. Focused gene expression analysis on HuR bound, immunoprecipitated RNA defined functional HuR downstream targets (including deoxycytidine kinase). Current studies will reveal and validate the importance of these downstream mRNA targets in PARP-inhibitor metabolism and efficacy. We hypothesize that HuR may be central to PARPi effectiveness and may be useful in understanding PARPi de novo drug resistance mechanisms. Future work will reveal whether HuR status can be utilized as a predictive marker for PARP-inhibitor-based therapy and if all clinically available PARP-inhibitors engage HuR's regulation of unique mRNA cargoes in cancer cells upon treatment. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3643.
IMPACT OF HOSPITAL VOLUME ON IN-HOSPITAL MORTALITY AND PERI-PROCEDURAL COMPLICATIONS IN PERIPHERAL VASCULAR INTERVENTIONS OF LOWER LIMBS IN THE UNITED STATES
Authors: Nilay Patel, Shilpkumar Arora, Sidakpal Panaich, Nileshkumar Patel, Sopan Lahewala, Samir Patel, Vikas Singh, Ankit Chothani, Sohilkumar Manvar, Ghanshyambhai Savani, Neil Patel, Jay Patel, Shantanu Solanki, Badal Thakkar, Vinaykumar Panchal, Sunny Jhamnani, Abhishek Deshmukh, Apurva Badheka
Journal: Journal of the American College of Cardiology (2015)